Spanish 1st Qtr 1994 Pharma Spending

4 September 1994

In the first quarter of 1994 Spanish public spending on pharmaceuticals amounted to 159.4 billion pesetas ($1.2 billion), an increase of 7.9% on the like, year-earlier period and corresponding to 127.7 million prescriptions written, reports the Spanish Health Economics Office (OES).

The OES noted that the reduction in the rate of value-added tax had an effect on the monthly expenditure for December 1992 and January 1993 which disguised the real spending behaviour for these two months, and also reflects on the percentage changes for the first quarter of 1994.

Taking the real spending value for the first quarter of 1993, public pharmaceutical spending would have been 151.6 billion pesetas instead of the reported 147.7 billion. The increase in spending for the first quarter of 1994 in real terms is 5.1%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight